Harold C. Simmons Comprehensive Cancer Center

Validation of the International Working Group 2023 response criteria for higher risk myelodysplastic syndromes/neoplasms using the International Consortium for Myelodysplastic Syndromes VALIDATE database and a randomized phase III trial

Response assessment criteria in patients with higher-risk myelodysplastic syndromes/neoplasms (HR-MDS) have been updated in the 2023 International Working Group (IWG) criteria. However, validation of these criteria has been limited to date. We analyzed overall survival (OS) by be...

Physician- and Practice-Level Variation in Clinical Trial Participation Among Patients With Advanced Cancer

Importance Clinical trial enrollment is essential to advancing cancer care, yet participation among patients with advanced cancer remains low. While patient-level barriers are frequently cited, the role of health care delivery factors—specifically physician- and practice-level va...

Real‐world outcomes of nivolumab‐ AVD and brentuximab vedotin‐ AVD in paediatric and adult advanced‐stage Hodgkin lymphoma

Summary Brentuximab vedotin (BV)‐doxorubicin, vinblastine and dacarbazine (AVD) and nivolumab (N)‐AVD have transformed the frontline treatment of advanced‐stage Hodgkin lymphoma (HL), yet real‐world comparative data remain limited. In this multicentre retrospective study across 1...